Archives
o2h Ventures backed Arecor enters into an exclusive formulation collaboration with Intas Pharmaceuticals 8 September, 2021
o2h Ventures backed In4Derm enters into an exclusive license agreement with VYNE Therapeutics 13 August, 2021
o2h Ventures ‘Knowledge Intensive Human Health EIS Fund’ invests into BiVictriX Therapeutics 5 August, 2021
Digital brain biomarker company Monument Therapeutics raises £2.6 million 20 July, 2021
o2h Ventures backed Arecor Granted Key US Patent 14 May, 2021
o2h Ventures backed Small Pharma Raises Cash to Fund Reverse Takeover on Toronto Stock Exchange 12 May, 2021
o2h Ventures backed In4Derm Announces a Strategic Partnership with a Nasdaq listed biotech with a >$200m Option License Agreement 11 May, 2021
Sunil Shah, CEO of o2h ventures, wins the Cambridge Independent Science and Technology Awards as CEO of the Year 16 April, 2021
University of Sussex and o2h Ventures Announce Creation and Investment in Stingray Bio, a Company for New Oncology Drugs Targeting the LMTK3 Kinase Pathway 8 April, 2021